01 Growing Adoption of Decentralized Clinical Trials in Veterinary Research Veterinary CROs are increasingly supporting decentralized clinical trial models that use remote monitoring, digital data collection, and virtual consultations to improve trial accessibility and efficiency. This transition enables broader participation of animal owners and veterinary clinics while reducing study timelines and operational costs. For example, CROs are integrating digital platforms for remote health tracking of companion animals during pharmaceutical trials.
02 Increasing Use of Real World Data for Veterinary Product Development The growing availability of veterinary health records and real-world evidence is transforming how animal healthcare products are evaluated and developed. This transition enables CROs to analyze clinical data from veterinary practices, improving treatment validation, safety assessment, and regulatory submissions. For example, Mars Veterinary Health leverages data from millions of pets across its global clinic network and supports research initiatives such as the Mars Petcare Biobank, which tracks 20,000 dogs and cats to identify disease patterns and improve preventive care strategies.
01 The veterinary CRO market forecasts continued investment activity driven by rising demand for animal health research outsourcing, increasing development of veterinary pharmaceuticals and biologics, and growing adoption of advanced clinical trial and regulatory support services. In 2026, the US FDA’s Center for Veterinary Medicine (CVM) announced FY2026 grant funding for the Animal and Veterinary Innovation Centers (AVICs) program to strengthen veterinary research and innovation. The funding will support up to five cooperative grants, renewable for up to four years, focusing on areas such as aquaculture drug development, minor species therapeutics, food safety, and antimicrobial stewardship. The initiative aims to build collaborations between the FDA and academic research institutions to address regulatory challenges and accelerate the development of veterinary products.
01 Increasing Development of Veterinary Pharmaceuticals and Growing Pet Ownership & Companion Animal Healthcare Spending Drives Market The rising investment in veterinary drug discovery, vaccines, and biologics increases the need for specialized CRO capabilities, driving demand for outsourced research services. Pharmaceutical and biotechnology companies are using CROs to access regulatory expertise, clinical trial management, and specialized animal testing facilities without expanding internal infrastructure. Companies such as Zoetis and Boehringer Ingelheim Animal Health collaborate with external research partners to support development and evaluation of veterinary therapeutics.The increasing adoption of pets and rising spending on advanced companion animal healthcare are driving demand for new veterinary treatments and clinical studies. This growth encourages pharmaceutical companies to conduct more clinical trials for chronic conditions, preventive therapies, and specialty medicines, increasing reliance on veterinary CRO services. This expansion of companion animal healthcare innovation is strengthening demand for veterinary CROs and specialized trial management services.
01 High Regulatory Complexity and Limited Availability of Specialized Veterinary Research Infrastructure Restrain Market Expansion Strict regulatory requirements for veterinary clinical research increase operational complexity for CROs, as studies require compliance with different animal safety, efficacy, and approval guidelines across regions. These regulatory variations increase documentation needs, trial timelines, and operational costs. As CROs must maintain specialized regulatory expertise and quality systems, smaller service providers face challenges in scaling operations, which limits faster adoption of outsourced veterinary research services.The shortage of advanced veterinary research facilities, species-specific testing centers, and skilled professionals limits the capacity of CROs to manage complex clinical studies. Establishing specialized animal research infrastructure requires significant capital investment and operational expertise. These infrastructure limitations increase service costs and reduce accessibility for pharmaceutical companies, particularly in emerging markets where veterinary CRO adoption remains dependent on available research capabilities.
01 Expansion of Precision Medicine and Growth of Digital Veterinary Platforms Offer Growth Opportunities to Market Players The increasing adoption of precision medicine in animal healthcare creates opportunities for veterinary CROs to support biomarker discovery, genetic analysis, and personalized treatment studies. CROs with advanced laboratory capabilities and data analytics platforms can help pharmaceutical companies develop targeted therapies for companion animals and livestock. This opportunity is expected to expand as veterinary medicine moves toward more personalized and data-driven treatment approaches.The rising use of digital health tools, wearable devices, and remote monitoring systems creates opportunities for veterinary CROs to support decentralized trials and real-world evidence generation. Companies offering data management, clinical analytics, and digital trial solutions can help animal health companies improve research efficiency and reduce study timelines. For example, Mars Veterinary Health leverages its global veterinary network and clinical data capabilities to support research initiatives. Increasing digitalization of veterinary care is expected to create new service opportunities for CRO providers.
01 Difficulty in Recruiting Suitable Animal Study Participants and Increasing Competition from In-house Research Capabilities Challenges Market Growth The availability of suitable animals for clinical trials remains a challenge for veterinary CROs, as studies require specific breeds, disease conditions, age groups, and controlled environments. Limited access to qualified study populations can delay trial timelines and increase operational costs. For example, rare disease studies in companion animals often struggle with patient recruitment, reducing the efficiency of clinical research programs and limiting faster expansion of veterinary CRO services.The growing ability of large animal health companies to develop internal research capabilities creates competitive pressure for veterinary CROs. Major pharmaceutical companies are investing in dedicated laboratories, digital platforms, and research teams to retain control over critical development activities. This shift can reduce outsourcing opportunities for CRO providers and challenge their ability to secure long-term partnerships with established animal health companies.